Biomarkers to optimize the window of opportunity in patients with early arthritis

To validate galectin-1 serum levels as a diagnostic biomarker, to improve the implementation of the «window of opportunity» period in which the response to immunomodulatory therapies is better.
Methods: samples and clinical data from the IntegrAR cohort (rheumatoid arthritis and early arthritis from three 3rd level hospitals in the Community of Madrid), the PERSEO cohort (early spondyloarthritis) and the different populations of immune-mediated diseases from the IMID-kit Biobank.
* As for galectin 1 (and other molecules that may be related to its expression such as galectin 9 and IL6), plasma or serum levels will be measured by ELISA in different populations (controls, rheumatoid arthritis [RA], spondyloarthritis, systemic lupus erythematosus, inflammatory bowel disease, etc.) to validate it as a possible biomarker for the early diagnosis of RA. Specific cut-off points and positive predictive value (PPV) and negative predictive value (NPV) will be estimated.